Logo image of ROSE

ROSE HILL ACQUISITION CORP-A (ROSE) Stock Fundamental Analysis

NASDAQ:ROSE - Nasdaq - KYG7637J1076 - Common Stock - Currency: USD

11.66  -0.02 (-0.17%)

Fundamental Rating

2

Taking everything into account, ROSE scores 2 out of 10 in our fundamental rating. ROSE was compared to 0 industry peers in the Unkown industry. ROSE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ROSE does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ROSE was profitable.
ROSE had a positive operating cash flow in the past year.
In multiple years ROSE reported negative net income over the last 5 years.
In multiple years ROSE reported negative operating cash flow during the last 5 years.
ROSE Yearly Net Income VS EBIT VS OCF VS FCFROSE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 100M -100M -200M

1.2 Ratios

Industry RankSector Rank
ROA 135.86%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROSE Yearly ROA, ROE, ROICROSE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 -20K -40K -60K -80K

1.3 Margins

ROSE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ROSE Yearly Profit, Operating, Gross MarginsROSE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 20 -20 40 -40 60 80

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for ROSE remains at a similar level compared to 1 year ago.
ROSE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ROSE Yearly Shares OutstandingROSE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2021 2022 10M 20M 30M 40M
ROSE Yearly Total Debt VS Total AssetsROSE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2021 2022 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 8.49 indicates that ROSE is not in any danger for bankruptcy at the moment.
ROSE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 0
Altman-Z 8.49
ROIC/WACCN/A
WACCN/A
ROSE Yearly LT Debt VS Equity VS FCFROSE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2021 2022 0 100M -100M 200M -200M 300M

2.3 Liquidity

Industry RankSector Rank
Current Ratio 0
Quick Ratio 0
ROSE Yearly Current Assets VS Current LiabilitesROSE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2021 2022 20M 40M 60M 80M 100M

More info and screens

0

3. Growth

3.1 Past

ROSE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -37.21%.
EPS 1Y (TTM)-37.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-900%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ROSE Yearly Revenue VS EstimatesROSE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M
ROSE Yearly EPS VS EstimatesROSE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 43.19 indicates a quite expensive valuation of ROSE.
When comparing the Price/Earnings ratio of ROSE to the average of the S&P500 Index (29.63), we can say ROSE is valued slightly more expensively.
Industry RankSector Rank
PE 43.19
Fwd PE N/A
ROSE Price Earnings VS Forward Price EarningsROSE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF 27.91
EV/EBITDA N/A
ROSE Per share dataROSE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 0.2 0.3 0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ROSE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ROSE HILL ACQUISITION CORP-A

NASDAQ:ROSE (11/20/2023, 8:00:03 PM)

11.66

-0.02 (-0.17%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.62%
Inst Owner Change0%
Ins Owners158.93%
Ins Owner Change0%
Market Cap61.68M
Analysts60
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 43.19
Fwd PE N/A
P/S N/A
P/FCF 27.91
P/OCF 27.91
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)0.27
EY2.32%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.42
FCFY3.58%
OCF(TTM)0.42
OCFY3.58%
SpS0
BVpS-0.02
TBVpS-0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 135.86%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 56.09%
Current Ratio 0
Quick Ratio 0
Altman-Z 8.49
F-Score7
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-37.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-900%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-87.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y315.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y315.28%
OCF growth 3Y-79%
OCF growth 5Y-47.2%